chr9-69035900-C-T
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 3P and 1B. PM2PP3BS1_Supporting
The NM_000144.5(FXN):c.118C>T(p.Arg40Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000662 in 1,487,292 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.00040 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00069 ( 1 hom. )
Consequence
FXN
NM_000144.5 missense
NM_000144.5 missense
Scores
3
7
9
Clinical Significance
Conservation
PhyloP100: 0.0210
Genes affected
FXN (HGNC:3951): (frataxin) This nuclear gene encodes a mitochondrial protein which belongs to the FRATAXIN family. The protein functions in regulating mitochondrial iron transport and respiration. The expansion of intronic trinucleotide repeat GAA from 8-33 repeats to >90 repeats results in Friedreich ataxia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.793
BS1
Variant frequency is greater than expected in population nfe. gnomad4_exome allele frequency = 0.000692 (924/1335348) while in subpopulation NFE AF= 0.000842 (890/1057314). AF 95% confidence interval is 0.000795. There are 1 homozygotes in gnomad4_exome. There are 440 alleles in male gnomad4_exome subpopulation. Median coverage is 36. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FXN | NM_000144.5 | c.118C>T | p.Arg40Cys | missense_variant | 1/5 | ENST00000484259.3 | NP_000135.2 | |
FXN | NM_181425.3 | c.118C>T | p.Arg40Cys | missense_variant | 1/5 | NP_852090.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FXN | ENST00000484259.3 | c.118C>T | p.Arg40Cys | missense_variant | 1/5 | 3 | NM_000144.5 | ENSP00000419243.2 | ||
ENSG00000285130 | ENST00000642889.1 | c.118C>T | p.Arg40Cys | missense_variant | 1/25 | ENSP00000493780.1 |
Frequencies
GnomAD3 genomes AF: 0.000401 AC: 61AN: 151944Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
61
AN:
151944
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000299 AC: 27AN: 90414Hom.: 0 AF XY: 0.000255 AC XY: 13AN XY: 50990
GnomAD3 exomes
AF:
AC:
27
AN:
90414
Hom.:
AF XY:
AC XY:
13
AN XY:
50990
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000692 AC: 924AN: 1335348Hom.: 1 Cov.: 36 AF XY: 0.000668 AC XY: 440AN XY: 658314
GnomAD4 exome
AF:
AC:
924
AN:
1335348
Hom.:
Cov.:
36
AF XY:
AC XY:
440
AN XY:
658314
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000401 AC: 61AN: 151944Hom.: 0 Cov.: 33 AF XY: 0.000431 AC XY: 32AN XY: 74206
GnomAD4 genome
AF:
AC:
61
AN:
151944
Hom.:
Cov.:
33
AF XY:
AC XY:
32
AN XY:
74206
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Aug 22, 2024 | The FXN c.118C>T; p.Arg40Cys variant (rs145854903, ClinVar Variation ID 264451) is reported along with a likely pathogenic MYBPC3 variant in an individual with hypertrophic cardiomyopathy (Van Driest 2005). This variant is found predominantly in the non-Finnish European population with an allele frequency of 0.07% (36/48340 alleles) in the Genome Aggregation Database (v2.1.1). In vitro functional analysis of the variant protein showed defective cleavage leading to poor protein maturation; however, both FXN mRNA and protein levels were unaffected in patient’s cultured fibroblasts (Van Driest 2005). Additionally, expression of FXN mutant protein in yeast devoid of endogenous FXN were phenotypically indistinguishable. Computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.597). Due to conflicting information, the clinical significance of this variant is uncertain at this time. References: Van Driest SL et al. Molecular and functional characterization of a human frataxin mutation found in hypertrophic cardiomyopathy. Mol Genet Metab. 2005 Aug. PMID: 15936968. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Dec 26, 2023 | Reported in the heterozygous state in an individual with hypertrophic cardiomyopathy, however the individual also harbored a variant in MYBPC3 (PMID: 15936968); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 15936968) - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 16, 2024 | Variant summary: FXN c.118C>T (p.Arg40Cys) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0003 in 90414 control chromosomes (gnomAD). This frequency is not significantly higher than estimated for a pathogenic variant in FXN causing Friedreich Ataxia (0.0003 vs 0.0011), allowing no conclusion about variant significance. c.118C>T has been reported in the heterozygous state in an individual affected with hypertrophic cardiomyopathy (Van Driest_2005). However, this individual was also found carrying MYBPC3 c.2429G>A (p.Arg810His), which may have contributed to the patient's phenotype. This report does not provide unequivocal conclusions about association of the variant with Friedreich Ataxia. Van Driest_2005 also provided experimental evidence demonstrating that the variant prevented the cleavage of the inactive-precursor form of frataxin to the active-mature form. However, when the investigators examined protein levels in patient fibroblasts, the levels of mature frataxin were similar to those seen in controls, not allowing for convincing conclusions about the variant effect. The following publication has been ascertained in the context of this evaluation (PMID: 15936968). ClinVar contains an entry for this variant (Variation ID: 264451). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 23, 2017 | The p.R40C variant (also known as c.118C>T), located in coding exon 1 of the FXN gene, results from a C to T substitution at nucleotide position 118. The arginine at codon 40 is replaced by cysteine, an amino acid with highly dissimilar properties. This variant co-occurred with a missense alteration in MYBPC3 in a male patient diagnosed with hypertrophic cardiomyopathy at 12 years of age. The same group performed in vitro studies of the p.R40C variant and showed it was more sensitive to oxidative stress under metabolically demanding conditions; however, a skin biopsy from the patient mentioned above showed normal levels of frataxin mRNA and protein (Van Driest SL, Mol. Genet. Metab. 2005 Aug; 85(4):280-5). This amino acid position is well conserved on limited sequence alignment. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Hypertrophic cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Advanced Laboratory Medicine, UC San Diego Health, University of California San Diego | Apr 18, 2018 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Uncertain
T
BayesDel_noAF
Pathogenic
CADD
Benign
DANN
Uncertain
DEOGEN2
Uncertain
T;.;.;T;.;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
.;T;T;T;T;T
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Benign
L;L;L;L;.;.
MutationTaster
Benign
A;A;A
PrimateAI
Uncertain
T
PROVEAN
Benign
.;N;N;.;.;.
REVEL
Uncertain
Sift
Uncertain
.;D;D;.;.;.
Sift4G
Benign
.;T;T;.;.;.
Polyphen
D;D;.;D;.;.
Vest4
0.27, 0.33
MVP
0.95
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at